H5N1 influenza vaccine (Indonesia strain) + AS03

The H5N1 influenza vaccine (Indonesia strain) + AS03 is a monovalent, inactivated, split-virion prepandemic vaccine developed by GSK. It is specifically designed to provide protection against the H5N1 subtype of the influenza A virus, utilizing the A/Indonesia/05/2005 strain as the antigenic component. The vaccine is formulated with the AS03 adjuvant system, a proprietary oil-in-water emulsion containing squalene, DL-α-tocopherol, and polysorbate 80. AS03 is known to enhance the magnitude and breadth of the immune response, enabling dose-sparing strategies and potentially offering cross-protection against drifted H5N1 strains. This vaccine has been evaluated in clinical trials for its safety and immunogenicity, particularly in prime-boost regimens, and is part of pandemic preparedness efforts. It is marketed under the brand name Adjupanrix in the European Union.

Brand names

Adjupanrix

Other names

H5N1/AS03AS03-adjuvanted H5N1 vaccineAS-03-adjuvanted H5N1 vaccineAS 03-adjuvanted H5N1 vaccineA/Indonesia/05/2005 (H5N1) vaccineprepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)